AAIC 2025 Abstract
Phase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease Patients
By Marwan N. Sabbagh, Stephen Macfarlane, Audrey Gabelle, Show 4 more authorsChristopher U. Missling
Trial in peopleInterventions
Abstract
Background: There are no approved oral disease‐modifying small molecule therapies for treatment of early Alzheimer’s disease (AD). Blarcamesine is an orally bioavailable small molecule that enhances autophagy through SIGMAR1 activation and restoration of cellular homeostasis in early AD.
